Real-world outcomes with avelumab + axitinib in patients with advanced renal cell carcinoma in Japan: subgroup analyses from the J-DART2 study by International Metastatic Renal Cell Carcinoma Database Consortium risk classification
Subgroup analyses from J-DART2 confirm the long-term real-world effectiveness of first-line avelumab + axitinib across IMDC risk groups in patients with aRCC in Japan. Our findings were consistent with previous analyses by IMDC risk and support the favorable benefit-risk profile of avelumab + axitinib in clinical practice in Japan.
Authors
- Masatoshi Eto (ORCID: https://orcid.org/0000-0002-3312-9930)
- Toshinari Yamasaki
- Nobuo Shinohara (ORCID: https://orcid.org/0000-0002-6695-294X)
- Masahiro Kajita (ORCID: https://orcid.org/0000-0002-1319-0398)
- Norihiko Tsuchiya (ORCID: https://orcid.org/0000-0003-4242-2618)
- Takashi Karashima (ORCID: https://orcid.org/0000-0001-7338-8059)
- Tomoaki Miyagawa (ORCID: https://orcid.org/0000-0001-9867-0229)
- Y. Tomita
- Hiroshi Yaegashi (ORCID: https://orcid.org/0000-0003-3188-8834)
- Junya Furukawa (ORCID: https://orcid.org/0000-0001-8974-9218)
- Hirotsugu Uemura (ORCID: https://orcid.org/0000-0002-3665-9523)
- Junichi Hori
- Tomoyasu Sano
- Keisuke Monji
- Kazutoshi Fujita (ORCID: https://orcid.org/0000-0002-6774-7497)
- Taigo Kato (ORCID: https://orcid.org/0000-0002-8681-1407)
- Mototsugu Oya (ORCID: https://orcid.org/0000-0002-2048-4263)
- Toshiaki Tanaka (ORCID: https://orcid.org/0000-0001-8880-0042)
- Takayuki Ito
Institutions
- Kanazawa University (JP)
- Yamagata University (JP)
- Kyushu University (JP)
- Sapporo Medical University (JP)
- Jichi Medical University (JP)
- Asahikawa Medical University (JP)
- Hokkaido University (JP)
- Keio University Hospital (JP)
- Merck Biopharma Co., Ltd. (Japan) (JP)
- Niigata University Medical and Dental Hospital (JP)
- Kobe City Medical Center General Hospital (JP)
- Jichi Medical University Saitama Medical Center (JP)
- Nagoya University (JP)
- Kobe University (JP)
- Kōchi University (JP)
- Kindai University (JP)
- Tokushima University (JP)
- The University of Osaka (JP)
Publication Details
- Journal
- International Journal of Clinical Oncology
- Published
- 2025-02-11
- DOI
- https://doi.org/10.1007/s10147-024-02655-4
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pfizer
- Merck KGaA